Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: The Curious Case Of Proteostasis' Short Attack

Executive Summary

Proteostasis planned to raise cash this week, but scrapped the offering after an investor that shorted the stock published a scathing report. Also, Arena raised more than $350m in an offering after its positive Phase II etrasimod data, and venture capital flows to biopharma firms with big ideas.

Advertisement

Related Content

Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009
Aimmune Accelerates Commercial Planning For Peanut Allergy Drug
Arena Rises With Post-Belviq Pipeline
Pipeline Watch: Phase III Readouts For Talazoparib, Ampion, Avatrombopag
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
DBV Technologies Misses With Viaskin Peanut Allergy Patch
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field
Year's First 4 IPOs Go South As Proteostasis, AveXis Launch
BioNotebook: Six deals and a name change; Spectrum/CASI, Five Prime/GSK and more

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100623

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel